260 related articles for article (PubMed ID: 33742253)
1. A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors.
Wang WQ; Zhang WH; Gao HL; Huang D; Xu HX; Li S; Li TJ; Xu SS; Li H; Long J; Ye LY; Wu CT; Han X; Wang XH; Liu L; Yu XJ
J Gastroenterol; 2021 Apr; 56(4):395-405. PubMed ID: 33742253
[TBL] [Abstract][Full Text] [Related]
2. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Role of Examined and Positive Lymph Nodes after Distal Pancreatectomy for Non-Functioning Neuroendocrine Neoplasms.
Guarneri G; de Mestier L; Landoni L; Partelli S; Gaujoux S; Andreasi V; Nessi C; Dokmak S; Fontana M; Dousset B; Ruszniewski P; Bassi C; Falconi M; Sauvanet A
Neuroendocrinology; 2021; 111(8):728-738. PubMed ID: 32585667
[TBL] [Abstract][Full Text] [Related]
4. Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors.
Pulvirenti A; Javed AA; Landoni L; Jamieson NB; Chou JF; Miotto M; He J; Gonen M; Pea A; Tang LH; Nessi C; Cingarlini S; D'Angelica MI; Gill AJ; Kingham TP; Scarpa A; Weiss MJ; Balachandran VP; Samra JS; Cameron JL; Jarnagin WR; Salvia R; Wolfgang CL; Allen PJ; Bassiy C
Ann Surg; 2021 Dec; 274(6):1051-1057. PubMed ID: 31567347
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for short recurrence-free survival after resection of pancreatic neuroendocrine tumor (PanNET) liver metastases: which patients should undergo resection?
Masui T; Nagai K; Anazawa T; Kasai Y; Sato A; Nakano K; Uchida Y; Yogo A; Kawaguchi Y; Takaori K; Uemoto S
Scand J Gastroenterol; 2020 Apr; 55(4):479-484. PubMed ID: 32223573
[No Abstract] [Full Text] [Related]
6. Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study.
Zhang P; Li YL; Qiu XD; Luo J; Shi YF; Sun YL; Su F; Qi ZR; Tan HY
World J Surg Oncol; 2019 Apr; 17(1):66. PubMed ID: 30975157
[TBL] [Abstract][Full Text] [Related]
7. A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors.
Sho S; Court CM; Winograd P; Toste PA; Pisegna JR; Lewis M; Donahue TR; Hines OJ; Reber HA; Dawson DW; Tomlinson JS
J Gastrointest Surg; 2019 Jul; 23(7):1392-1400. PubMed ID: 30353489
[TBL] [Abstract][Full Text] [Related]
8. Comparison of WHO Classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors.
Liu TC; Hamilton N; Hawkins W; Gao F; Cao D
Am J Surg Pathol; 2013 Jun; 37(6):853-9. PubMed ID: 23598967
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of CT-based radiomics in grade 1-2 pancreatic neuroendocrine tumors.
Heo S; Park HJ; Kim HJ; Kim JH; Park SY; Kim KW; Kim SY; Choi SH; Byun JH; Kim SC; Hwang HS; Hong SM
Cancer Imaging; 2024 Feb; 24(1):28. PubMed ID: 38395973
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
[TBL] [Abstract][Full Text] [Related]
11. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
[TBL] [Abstract][Full Text] [Related]
12. Pre- and intraoperative diagnostic requirements, benefits and risks of minimally invasive and robotic surgery for neuroendocrine tumors of the pancreas.
Gharios J; Hain E; Dohan A; Prat F; Terris B; Bertherat J; Coriat R; Dousset B; Gaujoux S
Best Pract Res Clin Endocrinol Metab; 2019 Oct; 33(5):101294. PubMed ID: 31351817
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of neutrophil-lymphocyte ratio in resectable pancreatic neuroendocrine tumors with special reference to tumor-associated macrophages.
Harimoto N; Hoshino K; Muranushi R; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Araki K; Hosouchi Y; Suzuki H; Arakawa K; Hirai K; Fukazawa T; Ikota H; Shirabe K
Pancreatology; 2019 Sep; 19(6):897-902. PubMed ID: 31409525
[TBL] [Abstract][Full Text] [Related]
14. High-Grade Progression Confers Poor Survival in Pancreatic Neuroendocrine Tumors.
Botling J; Lamarca A; Bajic D; Norlén O; Lönngren V; Kjaer J; Eriksson B; Welin S; Hellman P; Rindi G; Skogseid B; Crona J
Neuroendocrinology; 2020; 110(11-12):891-898. PubMed ID: 31658459
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?
Merola E; Alonso Gordoa T; Zhang P; Al-Toubah T; Pellè E; Kolasińska-Ćwikła A; Zandee W; Laskaratos F; de Mestier L; Lamarca A; Hernando J; Cwikla J; Strosberg J; de Herder W; Caplin M; Cives M; van Leeuwaarde R
Oncologist; 2021 Apr; 26(4):294-301. PubMed ID: 33301235
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors.
Mandair D; Khan MS; Lopes A; Furtado O'Mahony L; Ensell L; Lowe H; Hartley JA; Toumpanakis C; Caplin M; Meyer T
J Clin Endocrinol Metab; 2021 Mar; 106(3):872-882. PubMed ID: 33180939
[TBL] [Abstract][Full Text] [Related]
17. Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor.
Gao H; Liu L; Wang W; Xu H; Jin K; Wu C; Qi Z; Zhang S; Liu C; Xu J; Ni Q; Yu X
Cancer Lett; 2018 Jan; 412():188-193. PubMed ID: 29107104
[TBL] [Abstract][Full Text] [Related]
18. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate.
McCall CM; Shi C; Cornish TC; Klimstra DS; Tang LH; Basturk O; Mun LJ; Ellison TA; Wolfgang CL; Choti MA; Schulick RD; Edil BH; Hruban RH
Am J Surg Pathol; 2013 Nov; 37(11):1671-7. PubMed ID: 24121170
[TBL] [Abstract][Full Text] [Related]
19. O-positive blood type is associated with prolonged recurrence-free survival following curative resection of pancreatic neuroendocrine tumors.
De Rycke O; Védie AL; Guarneri G; Nin F; De Flori C; Hentic O; Idri S; Sauvanet A; Rebours V; Cros J; Couvelard A; Ruszniewski P; de Mestier L
Pancreatology; 2020 Dec; 20(8):1718-1722. PubMed ID: 33032924
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of the preoperative main pancreatic duct dilation and neutrophil-to-lymphocyte ratio in pancreatic neuroendocrine tumors (PNETs) of the head after curative resection.
Zhou B; Zhan C; Xiang J; Ding Y; Yan S
BMC Endocr Disord; 2019 Nov; 19(1):123. PubMed ID: 31718651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]